source
- FDA delays review of Novo's hemophilia A drug denecimig over factory issuesUS regulators have extended the review of Novo's hemophilia A injection, denecimig, because of problems at an unnamed manufacturing facility. The FDA said ongoing remediation activities observed d…
- CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potentialCSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune diseas…